Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.76 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | AGXT | P21549 | 2/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CASR | P41180 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13718717 | 0.88 | TAAR1 (0.60) | TAAR1IDO1AGXTAOC3CHRM2 | |
| SCHEMBL13718930 | 0.88 | TAAR1 (0.60) | TAAR1IDO1AGXTAOC3CASR | |
| (S)-M-Methoxyamphetamine SCHEMBL269071 | 0.86 | TAAR1 (1.00) | TAAR1IDO1AGXTSIGMAR1 | |
| (S)-M-Methoxyamphetamine SCHEMBL3293027 | 0.86 | TAAR1 (1.00) | TAAR1IDO1AGXTSIGMAR1 | |
| (S)-M-Methoxyamphetamine SCHEMBL11461072 | 0.86 | TAAR1 (1.00) | TAAR1IDO1AGXTSIGMAR1 | |
| (S)-M-Methoxyamphetamine SCHEMBL30813013 | 0.86 | TAAR1 (1.00) | TAAR1IDO1AGXTSIGMAR1 | |
| SCHEMBL9538055 | 0.86 | TAAR1 (0.56) | TAAR1 | |
| SCHEMBL9071087 | 0.85 | TAAR1 (0.71) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL29365903 | 0.85 | TAAR1 (0.71) | TAAR1IDO1AGXTCHRM2CHRM1 | |
| SCHEMBL3163360 | 0.85 | TAAR1 (0.71) | TAAR1IDO1AGXTAOC3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0598750-A1 | INDOLES | Pfizer Limited (GB) | 1994-06-01 | — | — | EP | claimed |
| WO-1993002050-A1 | INDOLES | PFIZER LIMITED (GB) | 1993-02-04 | — | — | WO | claimed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | Artizan Biosciences, Inc. | 2023-11-09 | — | — | US | disclosed |
| US-20230348529-A1 | CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONAMIDATES | FORSCHUNGSVERBUND BERLIN EV (DE) | 2023-11-02 | — | — | US | disclosed |
| US-6107320-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 2000-08-22 | — | — | US | disclosed |
| WO-1998057910-A2 | CYCLOOXYGENASE-I SELECTIVE INHIBITORS AND THE USE THEREOF AS ANALGESIC, ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | LABORATORIOS MENARINI S.A. (ES) | 1998-12-23 | — | — | WO | disclosed |
| EP-0569193-B1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | SQUIBB & SONS INC (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5514696-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1996-05-07 | — | — | US | disclosed |
| CN-1030701-C | Indole derivatives and process for production thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-01-17 | — | — | CN | disclosed |
| EP-0569193-A1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-11-10 | — | — | EP | disclosed |
| WO-1993002050-A1 | INDOLES | PFIZER LIMITED (GB) | 1993-02-04 | — | — | WO | disclosed |
| CN-1056685-A | Indole derivatives and preparation method thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1991-12-04 | — | — | CN | disclosed |
| US-4013690-A | ORGANIC COMPOUNDS | SANDOZ LTD. (CH) | 1977-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | TAAR1 3775/4885IDO1 980/4885AGXT 3089/4885 |
| US-20230357139-A1 | SMALL MOLECULE INHIBITORS OF BACTERIAL TOXINS | FABP2, APC, SI | TAAR1 4761/4885IDO1 1059/4885AGXT 1607/4885 |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | NPFFR1, NPFFR2, NPBWR1 | TAAR1 88/4885IDO1 1166/4885AGXT 1830/4885 |
| US-20230348529-A1 | CHEMOSELECTIVE THIOL-CONJUGATION WITH ALKENE OR ALKYNE-PHOSPHONAMIDATES | PFAS, PHOSPHO1, PNKP | TAAR1 713/4885IDO1 4249/4885AGXT 1208/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | TAAR1 3661/4885IDO1 952/4885AGXT 1712/4885 |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | PLK1, PLK4, BUB1B | TAAR1 4724/4885IDO1 3449/4885AGXT 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.